Evidence map›Paper›PMID 34390925›Full record

ReviewCurrent opinion in virology2021

HIV-1 entry: Duels between Env and host antiviral transmembrane proteins on the surface of virus particles.

Tomoyuki Murakami, Akira Ono

Abstract readReview
In one paragraph

Review in Current opinion in virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Macropinosomes are a site of HIV-1 entry into primary CD4Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. PIPScience advances · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tomoyuki MurakamiDepartment of Microbiology & Immunology, University of Michigan Medical School, 5737 Medical Science Building II, 1150 W. Medical Center Drive, Ann Arbor, MI, 48109-0620, United States. Electronic address: tmurakam@umich.edu.
Akira OnoDepartment of Microbiology & Immunology, University of Michigan Medical School, 5737 Medical Science Building II, 1150 W. Medical Center Drive, Ann Arbor, MI, 48109-0620, United States.

Funding

Mechanisms that determine subcellular sites of HIV-1 assemblyR37AI071727 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Akira Ono · 2017 to 2026
$6.2M
Effects of virion-incorporated CD43, CD44, and PSGL-1 on HIV-1 infectionR21AI148381 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ONO, AKIRA · 2019 to 2020
$429k
NIAID NIH HHS R21 AI148381NIAID NIH HHS R37 AI071727
6 · The paper itself

Abstract

Human Immunodeficiency Virus type-1 (HIV-1) is the causative agent of AIDS. Its entry step is mediated by the envelope glycoprotein (Env). During the entry process, Env vastly changes its conformation. While non-liganded Env tends to have a closed structure, receptor-binding of Env opens its conformation, which leads to virus-cell membrane fusion. Single-molecule fluorescence resonance energy transfer (smFRET) imaging allows observation of these conformational changes on the virion surface. Nascent HIV-1 particles incorporate multiple host transmembrane proteins, some of which inhibit the entry process. The Env structure or its dynamics may determine the effectiveness of these antiviral mechanisms. Here, we review recent findings about the Env conformation changes on virus particles and inhibition of Env activities by virion-incorporated host transmembrane proteins.

Indexed as

HIV-1Antiviral AgentsHumansProtein ConformationVirionVirus InternalizationAntiviral Agents

Identifiers

PMID34390925
PMCPMC8500929

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.